Proffered paper session - Gastrointestinal tumours, colorectal
Proffered paper session - Gastrointestinal tumours, colorectal - Invited Discussant LBA20, 452O and LBA21
Date
22 Oct 2018Session
Proffered paper session - Gastrointestinal tumours, colorectalPresenters
Claus-Henning KoehneAuthors
C. KoehneAuthor affiliations
- Klinikum Oldenburg, 26133 - Oldenburg/DE
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Proffered paper session - Gastrointestinal tumours, colorectal - Invited Discussant LBA18_PR and LBA19
Presenter: Julien Taieb
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast
1777 - DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A
Presenter: Linda Henricks
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
3298 - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC)
Presenter: Heinz-Josef Lenz
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
6611 - Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
Presenter: Axel Grothey
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
5040 - TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).
Presenter: Chiara Cremolini
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
5222 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial.
Presenter: Sheela Rao
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.